南财智讯11月20日电，英特科技公告，公司于2025年11月20日召开第二届董事会审计委员会第十次会议 和第二届董事会第十九次会议，审议通过了《关于公司使用部分闲置募集资金（含超募资金）进行现金 管理的议案》。为提高资金使用效益，公司拟使用不超过人民币1.40亿元的暂时闲置募集资金进行现金 管理，投资于安全性高、流动性好的投资产品，包括但不限于结构性存款、协定存款、通知存款、大额 存单、收益凭证等。该事项尚需提交公司2025年第二次临时股东会审议通过，额度自股东会审议通过之 日起12个月内有效，在前述额度和期限范围内可滚动使用，且单个产品的投资期限不得超过12个月。公 司表示，本次现金管理不会影响募集资金投资项目进度和公司正常生产经营。 ...

智通财经11月20日讯诚达药业股份有限公司（证券代码：301201，简称"诚达药业"）今日发布公告称， 公司第六届董事会第二次会议已于11月19日审议通过《关于使用闲置自有资金进行现金管理的议案》， 拟使用不超过7亿元闲置自有资金进行低风险现金管理，以提升资金使用效率。该议案尚需提交公司股 东会审议，资金使用期限为股东会审议通过之日起12个月，期间可循环滚动使用。 投资方案：聚焦低风险流动性产品 公告显示，本次现金管理的投资品种将严格限定为风险较低、流动性好、期限不超过12个月的金融产 品，具体包括协定存款、通知存款、定期存款、结构性存款及金融机构理财产品等。公司明确表示，投 资产品不用于质押，亦不涉及以证券投资为目的的投资行为，且与理财产品发行主体无关联关系。 在额度与期限方面，公司及子公司合计投资上限为7亿元（含本数），资金可在上述额度及12个月有效 期内循环使用。公司董事会提请股东会授权管理层在额度范围内行使决策权，具体由财务部负责组织实 施。 风险控制：多重机制保障资金安全 尽管投资标的为低风险产品，公司仍针对潜在风险制定了系列控制措施： -动态跟踪机制：管理层及财 务部将持续监控产品投向与项目进展， ...

南财智讯11月19日电，诚达药业公告，公司于2025年11月19日召开第六届董事会第二次会议，审议通过 了《关于使用闲置募集资金进行现金管理的议案》。公司拟使用不超过人民币8.00亿元的暂时闲置募集 资金（含超募资金）进行现金管理，投资于安全性高、流动性好、期限不超过12个月的产品，包括但不 限于协定存款、通知存款、定期存款、结构性存款等现金管理类产品。使用期限自股东会审议通过之日 起12个月内有效，资金在额度范围内可滚动使用。该事项尚需提交公司股东会审议，不会影响募集资金 投资项目进度和公司正常生产经营。 ...

Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management, ensuring safety and liquidity while aiming to enhance returns for the company and its shareholders [2][3][20]. Investment Overview - **Investment Purpose**: The objective is to improve the efficiency of raised funds, ensuring that the use of these funds does not affect project construction and safety, while increasing returns for the company and shareholders [3]. - **Investment Amount**: The company intends to use up to RMB 300 million (including principal) for cash management, with a validity period of 12 months from the board's approval [4][16]. - **Source of Funds**: The cash management funds will come from temporarily idle raised funds from the company's initial public offering in 2019 [5]. Fund Management - **Fund Usage**: The raised funds from the IPO amounted to RMB 1,588.29 million, with a net amount of RMB 1,529.27 million after deducting issuance costs. All funds have been deposited in a special account approved by the board [6][24]. - **Investment Projects**: The raised funds are allocated for international pharmaceutical R&D and working capital, with adjustments made to project timelines as necessary [7][23]. Investment Methodology - **Investment Products**: The company will invest in low-risk, liquid, and capital-protected products such as agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates, with a maximum term of 12 months [10][16]. - **Implementation**: The board authorizes the management to make investment decisions within the approved limits and timeframe, with the finance department responsible for execution [11]. Cash Management Returns - **Return Allocation**: Earnings from cash management will be prioritized to cover any shortfalls in project investment amounts and will be managed according to regulatory requirements [12]. Recent Cash Management Situation - **Recent 12-Month Overview**: The authorization for cash management is valid for 12 months, allowing for rolling use of funds within the specified limits [13][14]. Board Approval Process - **Approval Details**: The board approved the cash management proposal on November 7, 2025, confirming that it would not affect the normal operation of the company's investment plans [15][21]. Impact on Company - **Operational Impact**: The planned cash management will not affect the normal operations or project funding of the company, and it aims to generate additional investment returns [20][29].

Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management to enhance fund efficiency and generate additional returns for the company and its shareholders [3][9][18]. Investment Overview - **Investment Purpose**: The aim is to improve the efficiency of raised fund usage while ensuring that it does not affect the construction and use of the raised fund projects [3]. - **Investment Amount**: The company intends to use up to RMB 300 million (including principal) for cash management, with a validity period of 12 months from the board's approval [4][14]. - **Source of Funds**: The funds for this cash management initiative come from the temporarily idle raised funds from the company's initial public offering in 2019 [5]. Investment Details - **Investment Products**: The company will invest in low-risk, liquid, and capital-protected financial products, including but not limited to agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [2][10]. - **Implementation Method**: The board authorizes the management to make investment decisions within the approved limits and timeframe, with the finance department responsible for execution [11][14]. Recent Cash Management Situation - The company has previously authorized cash management of up to RMB 400 million, with the latest authorization allowing for up to RMB 300 million [13][26]. Impact on the Company - The planned cash management will not affect the normal operation of the company's main business or the normal turnover of funds, and it aims to generate investment returns for the company and its shareholders [18][20]. Sponsor's Verification Opinion - The sponsor, UBS Securities, has confirmed that the cash management initiative has been approved by the board and complies with relevant laws and regulations, ensuring that it does not alter the intended use of raised funds [19][20].

Core Viewpoint - Company Rongzhi Rixin (688768) has announced plans to utilize idle raised funds and self-owned funds for cash management and entrusted wealth management, aiming to enhance capital efficiency and comply with regulations [1][2]. Financial Performance - As of October 30, 2025, Rongzhi Rixin's stock closed at 47.48 yuan, down 3.42% from the previous trading day, with a total market capitalization of 4.178 billion yuan [1]. - The stock opened at 49.16 yuan, reached a high of 49.17 yuan, and a low of 47.08 yuan, with a trading volume of 1.01 billion yuan and a turnover rate of 2.42% [1]. Fund Management Plans - The company plans to use up to 73 million yuan of temporarily idle raised funds for cash management and up to 500 million yuan of self-owned funds for entrusted wealth management, with a usage period not exceeding 12 months from the board's approval [1]. - Idle raised funds can be invested in various principal-protected products, including structured deposits, agreed deposits, notice deposits, time deposits, large certificates of deposit, treasury reverse repos, and income certificates [1]. - Self-owned funds may be allocated to money market funds, trust products, and entrusted loans [1]. Regulatory Compliance - The board of directors has approved the aforementioned plans without the need for shareholder meeting approval [1]. - Guoyuan Securities, the sponsor, has issued a special verification opinion stating that the plans comply with relevant regulations and will not affect the normal implementation of fundraising projects, thus supporting the efficiency of fund utilization [1].

Core Viewpoint - Yingli Automotive announced the approval of a proposal to use part of its idle raised funds for cash management, emphasizing the focus on high safety and liquidity investments [1] Group 1: Cash Management Proposal - The company will utilize up to 145 million yuan of temporarily idle raised funds for cash management [1] - Investments will include products with high safety, good liquidity, and capital protection agreements, with a maximum investment period of 12 months [1] - The cash management initiative is valid for 12 months from the date of board approval and allows for rolling use of funds within the specified limit [1] Group 2: Impact on Operations - The company stated that this cash management will not affect the progress of the raised fund investment projects or the normal production and operation of the company [1]

Group 1 - The company plans to use idle self-owned funds for cash management, with an amount totaling RMB 115 million, and has already recovered principal and earnings from matured financial products, yielding an investment return of RMB 1,751,446.57 [1] - The cash management products are low-risk investments, including structured deposits and guaranteed bank wealth management products, ensuring high liquidity and safety [2][3] - The board of directors approved the use of up to RMB 600 million for cash management, with the authorization valid for 12 months from the date of the shareholders' meeting [3][4] Group 2 - The company has implemented risk control measures, including only engaging with legally qualified financial institutions and conducting timely analysis of investment products [2] - The cash management activities will not affect the company's normal operations or cash flow needs, aiming to enhance fund utilization efficiency and overall performance [2][5] Group 3 - The company has proposed to appoint a new auditing firm, Crowe Horwath, for the 2025 fiscal year, replacing the previous firm, Tianjian, due to the latter's long-term service and to better align with the company's future development needs [8][20] - The decision to change the auditing firm has been approved by both the board of directors and the supervisory board, pending approval from the shareholders' meeting [20][21] Group 4 - The company intends to repurchase its shares through a centralized bidding method, with a total repurchase fund of no less than RMB 30 million and no more than RMB 50 million, at a maximum price of RMB 20.73 per share [26][30] - The repurchased shares will be used for future employee stock ownership plans or equity incentives, with the repurchase period lasting 12 months from the shareholders' meeting approval [30][31]

Core Viewpoint - The company plans to utilize up to 200 million yuan of idle raised funds for cash management to enhance fund efficiency and provide better returns for shareholders [1][6]. Fundraising Overview - The company raised a total of 421,694,471.25 yuan through a specific issuance of A-shares in 2024, with a net amount of 415,135,944.34 yuan after deducting issuance costs. The funds were fully received by September 29, 2025, and are intended to supplement the company's working capital [2]. Cash Management Plan - The company intends to use a maximum of 200 million yuan of idle raised funds for cash management, which can be rolled over within 12 months from the date of board approval. The funds will be returned to the designated account upon maturity, ensuring no impact on the company's normal funding needs [3]. Investment Product Types - The cash management will be strictly limited to capital-protected products, including but not limited to: - Fixed deposits, notice deposits, and time deposits - Structured deposits - Bank wealth management products - Income certificates from financial institutions - The investment products will have a maturity of no more than 12 months and can be transferred or withdrawn early. The company specifies that these products cannot be used for collateral, and the special settlement account must not hold non-raised funds or be used for other purposes [4]. Decision-Making and Execution Mechanism - The company authorizes the legal representative or their designee to exercise investment decision-making authority within the limits and validity period, responsible for selecting issuers, determining investment amounts and terms, and signing relevant agreements, with implementation handled by the finance department [5]. Risk Control and Compliance Assurance - The company emphasizes that, despite the rigorous selection of investment products, market volatility risks due to macroeconomic factors cannot be ruled out. To mitigate risks, the company has established multiple control measures: 1. The finance department will monitor product allocation and project progress in real-time, taking protective measures when risks are identified 2. The audit department will oversee the use and custody of funds, with independent directors able to hire professional institutions for auditing 3. An investment ledger and accounting system will be established to ensure transparent and standardized fund management 4. The company will strictly fulfill information disclosure obligations as required by the Shenzhen Stock Exchange [6]. Market Impact and Sponsor Opinion - The company states that this cash management will not affect the development of its main business or the planned use of raised funds, and there is no disguised change in the use of raised funds. By increasing the returns on idle funds, it will further enhance the company's profits, aligning with the interests of all shareholders. The sponsor, Changjiang Securities, has confirmed that the matter has undergone necessary approval procedures and complies with relevant regulations, expressing no objections [6].

Core Points - The company announced a board meeting scheduled for October 27, 2025, to review the proposal for cash management using idle fundraising [1] - The company plans to utilize up to 200 million yuan of temporarily idle fundraising for cash management, investing in low-risk, high-liquidity principal-protected products with a maximum term of 12 months [1] - The investment options include but are not limited to structured deposits, time deposits, large certificates of deposit, and agreed deposits [1] - The usage period for these funds will be valid for 12 months from the date of board approval, and the funds can be rolled over within the specified limit [1] - This decision will not affect the progress of fundraising investment projects or the company's normal production and operations [1]